Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,763,454

« Back to Dashboard

Summary for Patent: 5,763,454

Title: Crystal form of anhydrous 7-([1.alpha.,5.alpha.,6.alpha.]-6-amino-3-azabicyclo[3.1.0]hex-3-yl)-6-f luoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt
Abstract:The anhydrate of 7-([1.alpha.,5.alpha.,6.alpha.]-6-amino-3-azabicyclo[3.1.0]hex-3-yl)-6-flu oro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt has advantageous stability for formulation as an antibacterial agent.
Inventor(s): Handanyan; Lynne A. (New York, NY), Morris; Thomas A. (New York, NY), Hendrickson; Robert L. (New York, NY), Johnson; Phillip J. (New York, NY), Norris; Timothy (New York, NY)
Assignee: Pfizer, Inc. (New York, NY)
Application Number:08/849,300
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 5th percentile
Forward Citations: 4th percentile

No matches for this query

Premature patent expiration for: 5,763,454

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
5,763,454 June 09, 2006

Foreign Priority and PCT Information for Patent: 5,763,454

PCT Information
PCT FiledJune 06, 1995PCT Application Number:PCT/US95/07211
PCT Publication Date:December 12, 1996PCT Publication Number: WO96/39406

International Patent Family for Patent: 5,763,454

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina002753► subscribe
Australia5474996► subscribe
Australia703634► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.